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In 2002, the largest epidemic of Neisseria meningiti-
dis serogroup W135 occurred in Burkina Faso. The highest 
attack rate was in children <5 years of age. We describe 
cases from 1 district and evaluate the performance of the 
Pastorex test, which had good sensitivity (84%) and speci-
ﬁ  city (89%) compared with culture or PCR.
M
eningococcal epidemics in sub-Saharan Africa have 
been caused, until recently, mainly by Neisseria 
meningitidis serogroup A (1); strains of serogroup W135 
have been isolated sporadically (2). In 2000 and 2001, se-
rogroup W135 was associated with outbreaks in pilgrims to 
Mecca, Saudi Arabia, followed by several clusters of cases 
worldwide (3–5).
Laboratory conﬁ  rmation of meningococcal meningitis 
is conducted by using antigen detection in cerebrospinal 
ﬂ  uid (CSF), culture, or PCR techniques (6,7). The Pastorex 
latex agglutination test (Bio-Rad Laboratories, Marnes-La-
Coquette, France) is the most common rapid test used in 
the ﬁ  eld to detect N. meningitidis serogroup W135 antigen, 
although it cannot differentiate serogroups W135 and Y.
In January 2002, a preventive mass-vaccination cam-
paign with a bivalent A-C polysaccharide vaccine started in 
Burkina Faso in districts with low vaccine coverage in 2001. 
In the week of January 28, 2002, Pama District crossed the 
epidemic threshold of 10 cases/100,000 per week (8). This 
district had achieved 100% vaccination coverage of the tar-
get population (2–29 years of age) in 2001 (Médecins sans 
Frontières internal report). Four weeks later, 4 other dis-
tricts that had achieved ≥80% vaccination coverage in 2001 
(Epicentre internal comm.) crossed the epidemic threshold 
(8). By mid-March 2002, the World Health Organization 
(WHO) Collaborating Centre for Reference and Research 
on Meningococci (CCRRM) in Oslo, Norway, conﬁ  rmed 
most of these cases as caused by serogroup W135. Because 
the A-C vaccine could not provide protection against sero-
group W135, the Ministry of Health ended the vaccination 
campaign.
The epidemic in Pissy District (population 520,314 in 
2002) was investigated by the Burkina Faso Ministry of 
Health and WHO. We evaluated the Pastorex test for de-
tecting N. meningitidis serogroup W135 in patients at Pissy 
Medical Health Centre (MHC).
The Study
A suspected case was deﬁ  ned as a febrile syndrome of 
sudden onset, associated with headache, stiff neck, or vom-
iting. A probable case was any suspected case with either a 
positive or doubtful result on direct microscopic examina-
tion of CSF. A conﬁ  rmed case was a probable case with 
serogroup identiﬁ  cation in CSF by culture, Pastorex test, or 
PCR. Patients with suspected cases were hospitalized and 
treated with a suspension of chloramphenicol in oil or an-
other antimicrobial drug, as appropriate (9). Patients with 
severe cases were routinely transferred to Yalgado Oué-
draogo National Hospital in Ouagadougou. Attack rates 
by age group were calculated for cases reported during 
weeks 6–18 (February 4–May 5) by using population data 
for Pissy District and standard age-group distributions for 
developing countries (10).
CSF samples from patients with suspected cases during 
weeks 17–20 (April 21–May 15) were examined at Pissy 
MHC by direct macroscopic and microscopic techniques, 
including Gram stain and leukocyte counts (as long as the 
CSF was not bloody). Pastorex rapid agglutination test was 
also used following the manufacturer’s instructions.
A positive result for direct microscopic examination 
was indicated by numerous organisms or >10 leukocytes/
mm3 CSF. A doubtful result was indicated by a rare or-
ganism and <10 leukocytes/mm3 CSF (or count not made). 
Any other result was considered negative. If results of di-
rect microscopy were positive or doubtful, the remaining 
CSF sample was placed in 2 bottles of trans-isolate me-
dium (provided by WHO CCRRM in Oslo). One bottle was 
sent for culture to the Charles de Gaulle Paediatric Hospital 
Laboratory in Ouagadougou. For quality control, the other 
was sent to WHO CCRRM for culture or PCR.
In Oslo, 100 μL of each CSF sample in trans-isolate 
medium was plated onto chocolate agar and chocolate agar 
containing 7.5 mg/L colimycin, 0.5 mg/L linocmycin, 1.0 
mg/L amphotericin B, and 5.0 mg/L trimethoprim. Plates 
were incubated at 35°C in an atmosphere of 10% CO2 for 
<3 days, and meningococci were identiﬁ  ed by standard 
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methods (11). PCR was performed as previously described 
(6,7) on samples that were either contaminated or culture 
negative for meningococci.
Performance of the Pastorex test was measured by 
calculating sensitivity and speciﬁ  city, by using culture or 
PCR results from WHO CCCRM as the comparison stan-
dard. Samples with contaminated cultures and inhibited 
PCR (clinical specimens may contain inhibitory substanc-
es [12]) were considered negative, as were undetermined 
results. Positive and negative predictive values (PPV and 
NPV, respectively) were also calculated.
Of 2,130 patients with suspected cases reported in Pissy 
District during weeks 6–18, the conditions of 1,325 (65%) 
were diagnosed and treated at Pissy MHC (Figure 1); 44 
died (case-fatality rate [CFR] 3%). Age was available for 
1,307 (99%) of 1,325 patients. The highest attack rate was 
in patients <1 year of age (1,092/100,000), followed by pa-
tients 1–4 years of age (660/100,000). The attack rate con-
tinued to decrease with age (Table 1). Vaccination history 
was provided by 1,137 patients with suspected cases (86%), 
of whom 791 (70%) had been vaccinated against meningi-
tis; information on year of vaccination was unknown.
Conﬁ  rmed case-patients showed typical clinical fea-
tures (13) (Table 2) and a CFR of 10%. Their ages ranged 
from 5 months to 19 years (median 4 years); the male:fe-
male ratio was 1.6:1. The 3 classic clinical signs of men-
ingitis (headache, fever, and stiff neck) were present in 10 
case-patients (33%).
During weeks 17–20, successful lumbar punctures 
(LPs) were performed in 260 patients with suspected cases 
at Pissy MHC. Thirty-one were positive for meningitis se-
rogroup W135 by culture, PCR, or Pastorex test. CSF was 
clear in 6 (19%) samples, cloudy in 22 (71%), and bloody 
in 3 (10%). Among 6 clear CSF samples, 3 had doubtful 
results by direct microscopy and were conﬁ  rmed only by 
Pastorex test.
Eighty-two CSF samples from all probable case-pa-
tients were sent to WHO CCCRM. These samples were 
tested by direct microscopy, and most were tested by Pas-
torex test in Burkina Faso. Sixty samples had doubtful 
results, and 22 had positive results by direct microscopy 
(Figure 2).
The Pastorex test on 64 samples tested by culture or 
PCR showed a sensitivity of 84% (95% conﬁ  dence interval 
[CI] 60%–97%) and a speciﬁ  city of 89% (95% CI 76%–
96%) for detection of serogroup W135. PPV and NPV for 
this test were 76% (95% CI 53%–92%) and 93% (95% CI 
81%–99%), respectively. 
Conclusions
The meningitis epidemic in Burkina Faso in 2002 was 
the largest reported outbreak caused by N. meningitidis se-
rogroup W135 to date (3,13), with nearly 13,000 suspected 
cases (9). We report a portion of this epidemic at 1 health 
center, which represented ≈10% of suspected cases nation-
wide. Attack rate was highest in patients <5 years of age and 
decreased with age. Symptoms and CFR of conﬁ  rmed case-
patients were typical for meningitis. The Pastorex test had 
adequate sensitivity (84%) and speciﬁ  city (89%) for detect-
ing the W135 serogroup, similar to those found under ideal 
laboratory conditions (85% and 97%, respectively [14]).
An effective public awareness campaign and fear in the 
population (because of lack of suitable vaccine) resulted in 
large numbers of patients with suspected cases arriving at 
health centers throughout the country, and more LPs were 
conducted than expected. This situation⎯and the case 
deﬁ  nition, which was sensitive but not speciﬁ  c⎯explained 
why of 260 LPs performed in a 4-week period at the end of 
the epidemic, only 31 were positive. Routine transfer of 
severe case-patients from Pissy MHC to the national hos-
pital explained the lower CFR reported from Pissy MHC 
(3%) than for the whole epidemic (12%; [9]).
During this study, 25% of CSF samples analyzed with 
Pastorex test were unreadable, which may have been caused 
by differences in the serogroup W135/Y reaction in this 
test. In addition, difﬁ  culties in reading this test (possibly 
because of a lack of expertise in reading agglutination test 
results) have been reported in the ﬁ  eld during epidemics.
The Pastorex test provides faster results than either 
Table 1. Attack rates per 100,000 population by age group for 
suspected meningitis cases, Pissy Medical Health Centre, 
Burkina Faso* 
Age group, y  Population No. cases  Attack rate/100,000 
<1 19,772 216 1,092
1–4 68,681 453 660
5–14 145,688 289 198
15–29 145,688 220 151
>30 140,485 129 92
All 520,314 1,307 251
*Weeks 6–18 (Feb 4–May 5), 2002 (n = 1,307). Population data are for 
the entire district of Pissy. 
Figure 1. Number of meningitis cases (N = 1,325) and deaths 
reported during weeks 6–18 (February 4–May 5) at Pissy Medical 
Health Centre, Burkina Faso, 2002.DISPATCHES
culture or PCR (minutes vs. days) and requires less train-
ing and no specialized equipment other than a refrigera-
tor, centrifuge, and water bath. It is thus more appropriate 
for developing countries with limited resources (15), de-
spite relatively high costs (in 2005 kits cost ≈€11 per CSF 
sample analyzed). The high NPV of this test and its rapid-
ity make it an important case management tool because 
cases of nonmeningococcal meningitis during an outbreak 
require different treatment. Other studies have shown this 
test to have high sensitivity and speciﬁ  city under ideal 
conditions for both serogroups A (14,15) and W135 (14). 
Further study is needed to conﬁ  rm the validity of this test 
under epidemic conditions in the ﬁ  eld, particularly read-
ibility of results for serogroup W135.
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